Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at assumed coverage on shares of Omeros (NASDAQ:OMERGet Rating) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, UBS Group lowered shares of Omeros from a buy rating to a neutral rating in a report on Thursday, December 8th.

Omeros Price Performance

Omeros stock opened at $3.54 on Thursday. The stock has a market cap of $222.42 million, a price-to-earnings ratio of 4.72 and a beta of 1.02. Omeros has a 12-month low of $1.74 and a 12-month high of $7.75. The company has a quick ratio of 7.30, a current ratio of 3.25 and a debt-to-equity ratio of 2.58. The business’s 50-day simple moving average is $3.61 and its 200 day simple moving average is $3.28.

Institutional Trading of Omeros

A number of hedge funds have recently modified their holdings of the company. Ronald Blue Trust Inc. acquired a new position in Omeros during the second quarter valued at approximately $30,000. Coldstream Capital Management Inc. acquired a new position in shares of Omeros in the 4th quarter valued at $40,000. Laurion Capital Management LP bought a new stake in shares of Omeros in the 2nd quarter valued at $49,000. Lesa Sroufe & Co acquired a new stake in Omeros during the 3rd quarter worth $56,000. Finally, Barclays PLC lifted its holdings in Omeros by 732.1% during the fourth quarter. Barclays PLC now owns 30,057 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 26,445 shares in the last quarter. 32.64% of the stock is currently owned by institutional investors and hedge funds.

Omeros Company Profile

(Get Rating)

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.

Featured Articles

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with's FREE daily email newsletter.